Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07824960) titled 'Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma' on Sept. 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of Virginia
Condition:
Pancreatic Cancer
PDAC - Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Carcinoma
Locally Advanced Pancreatic Cancer
Intervention:
Drug: Avutometinib (VS-6766) + Defactinib (VS-6063)
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: October 1, 2026...